JP2013512256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512256A5 JP2013512256A5 JP2012541206A JP2012541206A JP2013512256A5 JP 2013512256 A5 JP2013512256 A5 JP 2013512256A5 JP 2012541206 A JP2012541206 A JP 2012541206A JP 2012541206 A JP2012541206 A JP 2012541206A JP 2013512256 A5 JP2013512256 A5 JP 2013512256A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptides
- sequence
- construct
- lcrv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 241000607479 Yersinia pestis Species 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 229910052791 calcium Inorganic materials 0.000 claims 7
- 239000011575 calcium Substances 0.000 claims 7
- 230000004044 response Effects 0.000 claims 7
- 238000012217 deletion Methods 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 230000001105 regulatory effect Effects 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 4
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 3
- 241000607734 Yersinia <bacteria> Species 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 208000007089 vaccinia Diseases 0.000 claims 3
- 241000305071 Enterobacterales Species 0.000 claims 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 108091023045 Untranslated Region Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 244000005709 gut microbiome Species 0.000 claims 1
- 229940099472 immunoglobulin a Drugs 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 235000011073 invertase Nutrition 0.000 claims 1
- 239000001573 invertase Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 229940092253 ovalbumin Drugs 0.000 claims 1
- 108010066381 preproinsulin Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26414409P | 2009-11-24 | 2009-11-24 | |
| US61/264,144 | 2009-11-24 | ||
| PCT/US2010/058094 WO2011066454A1 (en) | 2009-11-24 | 2010-11-24 | Compositions, methods and uses for expression of enterobacterium-associated peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013512256A JP2013512256A (ja) | 2013-04-11 |
| JP2013512256A5 true JP2013512256A5 (enExample) | 2014-01-16 |
Family
ID=44066925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541206A Pending JP2013512256A (ja) | 2009-11-24 | 2010-11-24 | 腸内細菌関連ペプチドの発現に関する組成物、方法、および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9028809B2 (enExample) |
| EP (1) | EP2504029A4 (enExample) |
| JP (1) | JP2013512256A (enExample) |
| AU (1) | AU2010324731B2 (enExample) |
| CA (1) | CA2781645A1 (enExample) |
| WO (1) | WO2011066454A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10174100B1 (en) * | 2006-11-06 | 2019-01-08 | Microvax, Llc | Multivalent DNA composition for Yersinia pestis |
| EP3054006A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |
| CN107103128B (zh) * | 2017-04-19 | 2019-11-05 | 西北工业大学 | 基于多准则妥协解排序的多目标威胁评估方法 |
| JP7695607B2 (ja) * | 2021-06-18 | 2025-06-19 | トヨタ紡織株式会社 | シアノバクテリアの製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| US7901680B2 (en) * | 2005-10-19 | 2011-03-08 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) vaccines for cancer therapy |
| US7875280B2 (en) * | 2004-12-02 | 2011-01-25 | The University Of Chicago | Methods and compositions involving LcrV proteins |
| EP1954306A2 (en) * | 2005-10-25 | 2008-08-13 | Novartis Vaccines and Diagnostics S.r.l. | Compositions comprising yersinia pestis antigens |
| US8268327B2 (en) * | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| WO2009079564A2 (en) * | 2007-12-17 | 2009-06-25 | Emory University | Immunogenic compositions and methods of use thereof |
| CA2760315C (en) * | 2009-04-30 | 2019-05-28 | Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) | Modified immunization vectors |
-
2010
- 2010-11-24 US US13/511,652 patent/US9028809B2/en not_active Expired - Fee Related
- 2010-11-24 WO PCT/US2010/058094 patent/WO2011066454A1/en not_active Ceased
- 2010-11-24 JP JP2012541206A patent/JP2013512256A/ja active Pending
- 2010-11-24 EP EP10833974.8A patent/EP2504029A4/en not_active Withdrawn
- 2010-11-24 CA CA2781645A patent/CA2781645A1/en not_active Abandoned
- 2010-11-24 AU AU2010324731A patent/AU2010324731B2/en not_active Ceased
-
2015
- 2015-04-06 US US14/679,944 patent/US20150343046A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6818797B2 (ja) | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 | |
| DK2558581T3 (en) | POX VIRUS EXPRESSION SYSTEM | |
| JP6743154B2 (ja) | Ｈｂｖを処置するための手段及び方法 | |
| ES2898235T3 (es) | Secuencias de aminoácidos y de ácidos nucleicos de adenovirus de simio, vectores que las contienen, y sus usos | |
| CN101321781B (zh) | 一种核苷酸疫苗 | |
| US10059747B2 (en) | Crimean-congo haemorrhagic fever virus antigenic composition | |
| CN113666990B (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| US20230381297A1 (en) | Attenuated poxvirus vector based vaccine for protection against covid-19 | |
| JP2020516264A5 (enExample) | ||
| AU2022205166A1 (en) | Recombinant modified vaccinia virus Ankara (MVA) Foot and mouth disease virus (FMDV) vaccine | |
| WO2019115816A1 (en) | Hepatitis b immunisation regimen and compositions | |
| AU2022205163A1 (en) | Hepatitis B immunisation regimen and compositions | |
| CN103627718B (zh) | 表达ibv s1和n双抗原蛋白重组质粒及其构建方法和应用 | |
| JP2021507712A (ja) | エプスタインバールウイルス抗原構築物 | |
| JP2013512256A5 (enExample) | ||
| Li et al. | Immunoprotection of FliBc chimeric fiber2 fusion proteins targeting dendritic cells against Fowl adenovirus serotype 4 infection | |
| JP2020537526A (ja) | Ｒｓｖ抗原性タンパク質又はその断片をコードする２つの発現カセットを有するアデノウイルスベクター | |
| BR112020007413A2 (pt) | Vetores adenovirais com dois cassetes de expressão | |
| JP7240029B2 (ja) | フラビウイルスとリッサウイルスとのキメラワクチン | |
| JP2024512103A (ja) | ワクチンプラットフォームとしての高弱毒化複製可能組換えポックスウイルスおよびその利用方法 | |
| Basirnejad et al. | Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant | |
| Rojas et al. | Adenovirus as tools in animal health | |
| WO2022084663A1 (en) | Compositions and methods for inducing an immune response | |
| CN103405767A (zh) | 传染性法氏囊病病毒样颗粒与单克隆抗体组合双功能疫苗 | |
| JP7240390B2 (ja) | 増強されたプロモーター |